Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy
This trial is active, not recruiting.
|Sponsor||Iwate Medical University|
|Start date||October 2012|
|End date||March 2014|
|Trial size||500 participants|
|Trial identifier||NCT01905969, MIAST-NJBMR-12|
Adjuvant chemotherapy followed by curative gastrectomy for Stage II/III gastric cancer has improved disease free time and survival. However, there are still considerable number of patients experience relapse even after adjuvant chemotherapy. In an attempt to select patients who really benefit the postoperative adjuvant chemotherapy, we have identified potential biomarkers (NF-kappaB/JNK) from cell line panel screening followed by immunohistochemical validation. In the present study, we further validate the significance of the biomarkers in a larger set of clinical samples to see if chemotherapeutic response can be determined immediately after surgery.
NF-kB(+)/JNK(-) in curatively removed specimens
NF-kB(-)/JNK(+) in curatively removed specimens
Relapse free survival
time frame: 3 years
Male or female participants of any age.
- Pathologically confirmed gastric cancer.
- Operated before November 2009.
- Stage Ib/II(except for T1, T3N0)/III.
- Received postoperative (R0) adjuvant chemotherapy (S-1).
- Not received postoperative (R0) adjuvant chemotherapy (surgery alone).
- Signed informed consent to provide paraffin embedded tissue of removed specimens.
- With advanced neoplastic lesions other than gastric cancer.
- Paraffin embedded tissue is not available.
- Unknown S-1 treatment condition.
|Official title||Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1|
Call for more information